Clinical Trial

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

Study acronym: ALANIS
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study aims to evaluate the efficacy and safety of belantamab mafodotin in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed (ND) AL amyloidosis .
Protocol Amendment History 4 changes
critical Recruitment opened 2026-07-19
notable Trial sites expanded: 0 -> 5 locations 2026-07-19
notable Primary completion pushed: 2032-12-13 -> 2033-01-12 2026-07-19
minor Completion pushed: 2032-12-13 -> 2033-01-12 2026-07-19
Trial Details
NCT Number NCT07224672
Lead Sponsor GlaxoSmithKline
Conditions Amyloidosis
Enrollment 60 participants
Start Date 2026-06-24
Primary Completion 2033-01-12 (estimated)
Study Completion 2033-01-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-17